Holen Sie sich die Stockscreener-App
286.40
2.83%
-8.34
Schlusskurs vom Vortag:
$294.74
Offen:
$290.51
24-Stunden-Volumen:
355.19K
Relative Volume:
0.35
Marktkapitalisierung:
$7.16B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-31.23
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+6.49%
1M Leistung:
+59.90%
6M Leistung:
+518.31%
1J Leistung:
+260.16%
1-Tages-Spanne:
$281.60
$294.45
1-Wochen-Bereich:
$281.60
$317.72
52-Wochen-Spanne:
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
286.40 | 7.37B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines stock rises as FDA grants breakthrough designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock rises as FDA grants breakthrough designation - Investing.com Australia
Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status - Investing.com Nigeria
Praxis: Priced For Perfection Heading Into 2026 (NASDAQ:PRAX) - Seeking Alpha
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4%Here's Why - MarketBeat
Praxis Precision (PRAX) Shares Drop Amid Market Movement - GuruFocus
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock By Investing.com - Investing.com Nigeria
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock - Investing.com India
Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide - Yahoo Finance
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target - ts2.tech
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug - ts2.tech
Praxis Precision Medicines Stock Pre-Market (+12%) : FDA Breakthrough Therapy Designation for Ulixacaltamide - Trefis
Praxis Precision Medicines Stock Surges: What Drives the Wave? - StocksToTrade
Why Praxis Precision Medicines Stock Popped Today - Finviz
Why Praxis Precision Medicines Stock Popped Today - The Motley Fool
Praxis Precision Medicines: An Unexpected Surge? - timothysykes.com
Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG By Investing.com - Investing.com South Africa
PRAX Stock Rises 13% in Premarket Trading - GuruFocus
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines Soars on FDA Breakthrough Therapy Des - GuruFocus
Why Is Praxis Precision Medicines Stock Soaring Monday?Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation - Investing.com Nigeria
Praxis Precision (PRAX) Soars 14.7% on Market Uptick - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighTime to Buy? - MarketBeat
Praxis Precision Medicines (PRAX) Surges on FDA Breakthrough Des - GuruFocus
Jefferies reiterates Buy rating on Praxis Precision Medicines stock, cites FDA breakthrough designation - Investing.com India
Why did Praxis Precision stock surge 12% pre-market today? - MSN
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
PRAX Stock Gains as FDA Grants Breakthrough Therapy Status to Ul - GuruFocus
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? - Asianet Newsable
Praxis Precision Medicines stock soars after FDA grants Breakthrough status - Investing.com
Praxis Precision Medicines stock soars after FDA grants Breakthrough status By Investing.com - Investing.com South Africa
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide By Investing.com - Investing.com Nigeria
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide - Investing.com
PRAX Receives FDA Breakthrough Therapy Designation for Ulixacalt - GuruFocus
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG - Investing.com Nigeria
Praxis Wins FDA Breakthrough Status for Ulixacaltamide - TipRanks
Praxis Precision Medicines Receives Breakthrough Therapy Designation from FDA for Ulixacaltamide in Essential Tremor Treatment - Quiver Quantitative
Praxis Precision Medicines Receives Breakthrough Therapy Designation - TradingView — Track All Markets
Praxis Precision Medicines Announces the FDA Has Granted - GlobeNewswire
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):